[Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].
The French selegiline (S) multicenter trial was conducted in 1990 to test the possibility to improve symptomatology of de novo parkinsonian patients (PP) during the first three months of treatment by monotherapy S 10 mg/day. A randomized double blind placebo, parallel controlled trial was carried out on 93 patients in 13 neurologic centers. S appears superior to placebo. Global scores and motor subscores of UPDRS are improved (p < 0.001, p < 0.01) from the first to the third month. Side effects are minor (nausea, dysgueusia, vertigo, lipothymia) and hardly different in both groups. S thus appears as inducing a rapid and moderate symptomatic effect in de novo PP, during a 3 months long period of treatment.
D000368:Aged; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*
D012642:Selegiline
Essai de la sélégiline en monothérapie chez le parkinsonien de novo. Membres du groupe de l'essai français de la sélégiline chez le parkinsonien de novo.